BioCrossroads is a venture capital firm invests in life sciences industry based in Indiana. The firm operates early-stage life sciences venture funds investing in early-stage biotechnology, pharmaceutical, medical device, diagnostic, agtech, biotech and health information technology products and platforms.
Paul Silber serves as Co-Founding Principal at Blu Venture Investors. Silber also serves as Advisor at Evergreen Advisors and Insightin Health. Silber serves as Advisor at Evergreen Advisors and also serves as Board Member at Encore Path. He a native of Baltimore was the founder and President/CEO of In Vitro Technologies, (IVT), a bioscience company that provides products and services to pharmaceutical and biotechnology companies. After relocating to Baltimore in 1991, In Vitro grew from two employees to a staff of 70, including several employees in Europe. The company also expanded its international business to Japan, the U.K., and Germany, while bringing the products of international companies to their North American customers through strategic alliances and distribution relationships.
Evergreen Venture Partners is a venture capital firm that specializes in early stage and emerging growth investments. The firm invests in the communications, internet and media, software, healthcare, pharmaceuticals, medical devices and clean technology sectors.
Percy Nikora serves as Partner at Robin Hood Ventures. He is an Angel Investor. He is passionate about helping high-growth early stage companies achieve their full potential - from idea to exit. He is an experienced investor, entrepreneur, management consultant and Fortune 500 executive. He currently serves on the board of Cloudmine, is a member of Ben Franklin Technology Partner's Technology Investment Advisory Committee and also serves on boards of non-profits. In addition to angel investing, he owns a boutique technology focused management consulting firm and has held leadership positions at Pfizer, Wyeth Pharmaceuticals, Merrill Lynch and Dow Jones. He has successfully started, grown and exited several software companies.
Bay City Capital is a private equity and venture capital firm that invests in the life sciences industry, with a focus on investing in companies within the bio-pharmaceuticals, drug discovery, medical devices, nutrition, healthcare IT and medical diagnostics sectors. The firm specializes in seed, early stage, mid and late-stage, PIPES, mezzanine, bridge and turnaround investments. It typically invests in North America with a focus on the Great Lakes and Mid-Atlantic region. It was founded in 1997 and is based in San Francisco, California.
California Technology Ventures is a venture capital firm that invests in early and growth stage companies. The firm invests in the information and communications technology, computer hardware, telecommunications, electronics, semiconductors, software and systems, multi-media, internet, life sciences, bio-pharmaceuticals and medical devices sectors. The firm was founded in 1999 and is based in Pasadena, California.
Boston Millennia Partners is a venture capital and growth equity firm seeking to invest in companies operating in the healthcare technology, medical devices, life sciences, pharmaceutical development and business services sectors.
As a Managing Director at H.I.G. BioVentures, Bruce focuses on investment opportunities in the life sciences sector, including biopharmaceuticals, medical devices, and diagnostics. Bruce currently serves on the boards of Apollo Endosurgery, CardioFocus, Cerephex, and Clarus Therapeutics. Bruce has been active in the life sciences sector for more than 20 years. Prior to joining H.I.G., Bruce served most recently as Managing Director at Toucan Capital, an early-stage venture capital fund focusing on life science investments. While at Toucan, Bruce invested in leading drug and device companies throughout the U.S. Prior to Toucan, Bruce was a General Partner at GIV Venture Partners, a venture capital firm focused on early stage investments in the US, India, and China. Prior to his venture capital career, Bruce was Director of Business Development at IGEN International, where he was responsible for formulating and implementing IGEN's partnering and M&A strategies. Bruce started his career as a Research Manager at W.R. Grace & Co., focusing on medical devices. Bruce is on the boards of the Mid-Atlantic Venture Association, Adventist Healthcare, the University of Delaware Research Foundation, and the BioLife Fund of Virginia’s Center for Innovative Technology. Bruce holds a BSE in Chemical Engineering and BA in Mathematics from the University of Pennsylvania, a PhD in Chemical/Biomedical Engineering from the University of Delaware, and an MBA with High Distinction from Harvard Business School.